Core Insights - vTv Therapeutics has expanded its license agreement with Newsoara Biopharma, granting Newsoara global rights to develop and commercialize the PDE4 inhibitor HPP737, which is aimed at treating inflammation-mediated diseases [1][3] - The agreement includes an upfront payment of $20 million, potential future development milestones of approximately $50 million, sales milestones of up to $65 million, and tiered royalties based on net sales [2][3] Company Overview - vTv Therapeutics is a late-stage biopharmaceutical company focused on developing oral small molecule drug candidates for chronic diseases, particularly type 1 diabetes [8] - The company's lead product, cadisegliatin, is currently in a Phase 3 trial and has received Breakthrough Therapy designation from the FDA [6][8] Product Details - HPP737 is a selective phosphodiesterase type 4 (PDE4) inhibitor that has shown therapeutic activity in animal models of inflammation and has been well tolerated in phase 1 studies [3][4] - The drug aims to address unmet needs in inflammation-mediated diseases and may avoid gastrointestinal side effects commonly associated with other PDE4 inhibitors [4] Strategic Collaboration - The collaboration with Newsoara is seen as a strategic priority for vTv, enhancing its balance sheet and providing a significant source of potential value creation for shareholders [2][3] - Newsoara plans to leverage its development and commercialization capabilities to advance HPP737 and bring it to patients worldwide [3][9]

Core Viewpoint - Zevra Therapeutics, Inc. has been invited to ring the Nasdaq opening bell on February 9, 2026, highlighting its presence in the market and commitment to rare disease therapies [1]. Company Overview - Zevra Therapeutics is a commercial-stage company focused on developing therapies for rare diseases, specifically its lead product for Niemann-Pick disease type C (NPC), a rare neurodegenerative disorder [3]. - The company aims to broaden access to its therapies through geographic expansion and has a pipeline of programs targeting rare diseases [3]. - Zevra is committed to patient-centric values including accountability, integrity, innovation, and courage, with a goal of creating long-term value for patients, partners, and shareholders [3].

Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of a standardized, FDA-approved statin therapy evaluated in rigorous, well-designed clinical trials WAYNE, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commerc ...

Core Viewpoint - Sagimet Biosciences Inc. is advancing the development of denifanstat (ASC40), a fatty acid synthase (FASN) inhibitor, which has shown positive results in clinical trials for treating moderate to severe acne, indicating its potential as a novel therapeutic option in this area [1][2][3]. Clinical Results - The Phase 3 open-label trial (ASC40-304) enrolled 240 subjects who received denifanstat 50 mg once daily for up to 40 weeks, following a previous 12-week double-blind trial [4]. - Denifanstat demonstrated improvements in all efficacy endpoints beyond the 12-week results, including significant reductions in skin lesion counts and improvements in Investigator's Global Assessment (IGA) scores [5][6]. Safety Profile - Denifanstat was generally well tolerated, with only mild to moderate treatment-emergent adverse events (TEAEs) reported, including dry eye syndrome (5.5%) and dry skin (5.2%) [7]. - No serious adverse events (SAEs) related to denifanstat were reported, and all adverse events were manageable, with no permanent discontinuations due to treatment [7]. Market Context - Acne affects over 50 million people in the U.S., with a significant number requiring chronic management, highlighting the need for effective treatment options [9]. - The inhibition of FASN is considered a promising approach due to its role in sebum production and inflammatory pathways associated with acne [9].

Performance Highlights - New Yi Sheng (300502.SZ) expects net profit between 9.4 billion and 9.9 billion CNY, a year-on-year increase of 231.24% to 248.86% due to rising demand for high-speed optical modules driven by global computing power investments[4] - Han's Chip (688256.SH) anticipates net profit between 1.85 billion and 2.15 billion CNY, turning from a loss of 450 million CNY last year, benefiting from the growing demand for AI computing power[5] - Zhongji Xuchuang (300308.SZ) projects net profit between 9.8 billion and 11.8 billion CNY, a year-on-year growth of 89.50% to 128.17%, driven by strong customer investment in computing infrastructure[6] - Runze Technology (300442.SZ) expects net profit between 5 billion and 5.3 billion CNY, a year-on-year increase of 179.28% to 196.03%, largely due to non-recurring gains from public REITs issuance[10] Underperformance Highlights - Great Wall Motors (601633.SH) forecasts net profit of 9.912 billion CNY, a year-on-year decline of 21.71% due to increased marketing expenses and competitive pressures[36] - GAC Group (601238.SH) expects a net loss between 8 billion and 9 billion CNY, turning from a profit of 824 million CNY last year, impacted by fierce competition and increased asset impairment provisions[39] - Xiexin Integrated (002506.SZ) anticipates a net loss between 890 million and 1.29 billion CNY, shifting from a profit of 68 million CNY last year due to structural supply-demand issues in the photovoltaic industry[41] - Baile Tianheng (688506.SH) projects a net loss of around 1.1 billion CNY, down from a profit of 3.708 billion CNY last year, primarily due to increased R&D expenses[42] Industry Trends - Technology-driven sectors like AI and innovative pharmaceuticals are leading growth, with companies like New Yi Sheng and Han's Chip benefiting from strong demand and technological advancements[69] - Cost control is becoming a critical competitive advantage, particularly in the energy and manufacturing sectors, as seen with companies like Datang Power (601991.SH) benefiting from lower coal prices[70] - Traditional cyclical industries such as real estate and agriculture are facing significant downward pressure, with companies like Vanke (000002.SZ) and Tianbang Foods (002124.SZ) experiencing substantial losses due to market adjustments[72]

Core Insights - The article discusses the best long-term low volatility stocks to invest in, highlighting the importance of adapting to a changing economic landscape characterized by increased volatility and the emergence of new investment themes [1][3]. Group 1: Market Trends - Sherry Paul from Morgan Stanley emphasizes a shift from globalization to a "new world order," indicating a need for reimagining supply chains and partnerships, particularly in AI and automation manufacturing in the U.S. [2] - The current economic environment suggests increased volatility ahead, which is seen as a natural part of investing rather than a negative indicator [3]. Group 2: Investment Methodology - The selection of stocks is based on a methodology that identifies long-term stocks with stable fundamentals and a beta below 1, focusing on those with the highest number of hedge fund holders as of Q3 2025 [6]. - The rationale for focusing on hedge fund favorites is that imitating top stock picks can lead to market outperformance, as evidenced by a quarterly newsletter's significant returns since May 2014 [7]. Group 3: Company Highlights - **AstraZeneca PLC (NASDAQ:AZN)**: - The company is enhancing its weight management portfolio through a collaboration with CSPC Pharmaceuticals, focusing on next-generation therapies for obesity and type 2 diabetes [9]. - AstraZeneca will gain exclusive global rights outside of China to CSPC's weight management portfolio, which includes a clinical-ready asset and several preclinical programs [10][11]. - **International Business Machines Corporation (NYSE:IBM)**: - The company received a price target increase from Argus to $360, driven by strong Q4 performance attributed to GenAI and hybrid cloud momentum [13]. - RBC Capital also raised its price target to $361, citing solid free cash flow performance and exposure to secular themes, particularly from the z17 mainframe refresh cycle [14].

Core Viewpoint - Pharming Group announced that the FDA issued a Complete Response Letter (CRL) for its supplemental New Drug Application (sNDA) for Joenja® (leniolisib) as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS) [1][5] Regulatory Update - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data to reassess proposed doses [2] - An issue was identified with one of the analytical methods used for production batch testing, prompting the FDA to request further data and clarification [2] - Pharming plans to address the issues outlined in the CRL and intends to request a Type A meeting with the FDA to discuss next steps for resubmission [3] Clinical Data - The sNDA submission was based on positive results from a Phase III study showing improvements in lymphadenopathy and naïve B cells over 12 weeks, indicating a correction of the immune defect in children [4] - Safety data from 8 months of treatment indicated that all treatment-emergent adverse events were mild to moderate, with no serious drug-related adverse events reported [4] Market Context - Currently, there are no approved treatments for children with APDS under the age of 12 globally, highlighting the significance of Joenja's potential impact [5] - Joenja received FDA approval for treating APDS in patients aged 12 years and older in March 2023, which remains unaffected by the recent regulatory action [3][5] Disease Overview - APDS is a rare primary immunodeficiency characterized by severe recurrent infections and immune dysregulation, affecting approximately 1 to 2 people per million worldwide [6] - The condition is caused by variants in the PIK3CD or PIK3R1 genes, leading to hyperactivity of the PI3Kδ pathway, which impairs immune cell function [6] Product Information - Leniolisib is an oral PI3Kδ inhibitor approved in several countries as the first targeted treatment for APDS in patients aged 12 years and older [7] - The drug is currently under regulatory review in multiple regions and is being evaluated in clinical trials for other primary immunodeficiencies [8]

Core Insights - Bristol Myers Squibb Company (NYSE:BMY) is identified as one of the most undervalued large-cap stocks currently available for investment [1] - Analysts have raised price targets for Bristol Myers, indicating a positive outlook for the stock driven by pipeline progress and growth potential [2][3] Analyst Ratings and Price Targets - Piper Sandler increased its price target for Bristol Myers to $66 from $62, maintaining an Overweight rating, citing undervaluation due to the upcoming loss of exclusivity for Eliquis in the US [1] - Citi analyst Geoff Meacham raised the price target to $60 from $53 with a Neutral rating, highlighting favorable conditions for the biopharma sector heading into 2026 [2] - Leerink analyst David Risinger raised the price target to $60 from $54 with an Outperform rating, anticipating significant upside potential in 2026 due to a robust pipeline [3] Company Overview - Bristol Myers Squibb is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products globally, focusing on areas such as oncology, hematology, immunology, cardiovascular, and neuroscience [4]

Core Viewpoint - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as one of the most profitable stocks on NASDAQ, with recent price target increases from Truist Securities and Citigroup indicating strong investor confidence in the company's future performance [1][3]. Group 1: Price Target Adjustments - Truist Securities raised its price target on Gilead Sciences to $145 from $140 while maintaining a Buy rating, citing revisions in estimates for the drug YEZTUGO and updates on upcoming launches [2]. - Citigroup also increased its price target for Gilead Sciences to $156 from $140, maintaining a Buy rating, as part of a broader Q4 preview for biopharmaceutical stocks [3]. Group 2: Company Overview - Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer [4].

Group 1 - Maze Therapeutics' Senior Vice President of Finance, Amy Bachrodt, sold 5,000 shares for approximately $227,612 on January 22, 2026, following a strong performance of the company's stock [1][2] - The company has seen a remarkable 1-year price change of 172.38%, with a significant increase of 158% in 2025 after its IPO on January 31, 2025 [4][6] - Following the transaction, Bachrodt's direct ownership decreased to 12,965 shares, representing 0.0269% of the company's outstanding shares [8] Group 2 - Maze Therapeutics is a clinical-stage biotechnology company focused on developing precision medicines for renal, cardiovascular, and metabolic diseases, including obesity [5] - The company is advancing to later clinical stages for its medicines targeting kidney and metabolic diseases, which are expected to generate significant revenue upon trial completion [9] - The stock has shown consistent gains for nine months post-IPO, but investors should be cautious of potential short-term drawdowns due to the sustained high buying power [6][7]